CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression

Molecular Immunology

Volumn 46, Issue 8-9, 2009, Pages 1727-1735

  Batlle, Ana ^a,c   Papadopoulou, Vasiliki ^a   Gomes, Ana R ^b   Willimott, Shaun ^a,e   Melo, Junia V ^a,d   Naresh, Kikkeri ^a   Lam, Eric W F ^b   Wagner, Simon D ^a,e  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Bcl 6; Germinal centre; MAPK; Transcription

Indexed keywords

B LYMPHOCYTE RECEPTOR; BCR ABL PROTEIN; CD40 LIGAND; IMATINIB; IMMUNOGLOBULIN M ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 6;

ARTICLE; B LYMPHOCYTE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE CONTROL; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LYMPHOID CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD40; BLAST CRISIS; CELL LINE, TUMOR; CELLS, CULTURED; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; PALATINE TONSIL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-6; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 64149118374     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.02.003     Document Type: Article

References (49)

1. Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A., Nonoyama S., Bajorath J., Grosmaire L.S., Stenkamp R., Neubauer M., et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72 (1993) 291-300
2. Basso K., Klein U., Niu H., Stolovitzky G.A., Tu Y., Califano A., Cattoretti G., and Dalla-Favera R. Tracking CD40 signaling during germinal center development. Blood 104 (2004) 4088-4096
3. Batista F.D., Arana E., Barral P., Carrasco Y.R., Depoil D., Eckl-Dorna J., Fleire S., Howe K., Vehlow A., Weber M., and Treanor B. The role of integrins and coreceptors in refining thresholds for B-cell responses. Immunol. Rev. 218 (2007) 197-213
4. Bereschenko O.R., Gu W., and Dalla-Favera R. Acetylation inactivates the transcriptional repressor Bcl-6. Nat. Genet. 32 (2002) 606-613
5. Bernardin F., Collyn-d'Hooghe M., Quief S., Bastard C., Leprince D., and Kerckaert J.P. Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation. Oncogene 14 (1997) 849-855
6. Carrasco Y.R., Fleire S.J., Cameron T., Dustin M.L., and Batista F.D. LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity 20 (2004) 589-599
7. Cattoretti G., Chang C.C., Cechova K., Zhang J., Ye B.H., Falini B., Louie D.C., Offit K., Chaganti R.S., and Dalla-Favera R. BCL-6 protein is expressed in germinal-center B cells. Blood 86 (1995) 45-53
8. Cattoretti G., Pasqualucci L., Ballon G., Tam W., Nandula S.V., Shen Q., Mo T., Murty V.V., and Dalla-Favera R. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7 (2005) 445-455
9. Chattopadhyay A., Tate S.A., Beswick R.W., Wagner S.D., and Ko Ferrigno P. A peptide aptamer to antagonize BCL-6 function. Oncogene 25 (2006) 2223-2233
10. Craxton A., Shu G., Graves J.D., Saklatvala J., Krebs E.G., and Clark E.A. p38 MAPK is required for CD40-induced gene expression and proliferation in lymphocytes. J. Immunol. 161 (1998) 3225-3236
11. Deininger M.W., Vieira S., Mendiola R., Schultheis B., Goldman J.M., and Melo J.V. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 60 (2000) 2049-2055
12. Dent A.L., Hu-Li J., Paul W.E., and Staudt L.M. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13823-13828
13. Dent A.L., Shaffer A.L., Yu X., Allman D., and Staudt L.M. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276 (1997) 589-592
14. Diehl S.A., Schmidlin H., Nagasawa M., van Haren S.D., Kwakkenbos M.J., Yasuda E., Beaumont T., Scheeren F.A., and Spits H. STAT3-mediated up-regulation of BLIMP1 is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J. Immunol. 180 (2008) 4805-4815
15. C Duy, J.J. Yu, L. Cerchietti, L. Klemm, R. Nahar, Y.-M. Kim, N. Heisterkamp, G. Martinelli, Wolf-Karsten Hofmann, H. Jumaa, A. Melnick, B.H. Ye, M., Muschen, BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia Blood (ASH Annual Meeting Abstracts), (2008); 112: 295.
16. Elenitoba-Johnson K.S., Jenson S.D., Abbott R.T., Palais R.A., Bohling S.D., Lin Z., Tripp S., Shami P.J., Wang L.Y., Coupland R.W., Buckstein R., Perez-Ordonez B., Perkins S.L., Dube I.D., and Lim M.S. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 7259-7264
17. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., and Trzaskos J.M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273 (1998) 18623-18632
18. Fernandez de Mattos S., Essafi A., Soeiro I., Pietersen A.M., Birkenkamp K.U., Edwards C.S., Martino A., Nelson B.H., Francis J.M., Jones M.C., Brosens J.J., Coffer P.J., and Lam E.W. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol. Cell Biol. 24 (2004) 10058-10071
19. Foy T.M., Laman J.D., Ledbetter J.A., Aruffo A., Claassen E., and Noelle R.J. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med. 180 (1994) 157-163
20. Gallagher E., Enzler T., Matsuzawa A., Anzelon-Mills A., Otero D., Holzer R., Janssen E., Gao M., and Karin M. Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat. Immunol. 8 (2007) 57-63
21. Hamilton A., Elrick L., Myssina S., Copland M., Jorgensen H., Melo J.V., and Holyoake T. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 20 (2006) 1035-1039
22. Kilmon M.A., Wagner N.J., Garland A.L., Lin L., Aviszus K., Wysocki L.J., and Vilen B.J. Macrophages prevent the differentiation of autoreactive B cells by secreting CD40 ligand and interleukin-6. Blood 110 (2007) 1595-1602
23. Mathur R.K., Awasthi A., Wadhone P., Ramanamurthy B., and Saha B. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat. Med. 10 (2004) 540-544
24. Niu H., Ye B.H., and Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 12 (1998) 1953-1961
25. Nonoyama S., Hollenbaugh D., Aruffo A., Ledbetter J.A., and Ochs H.D. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J. Exp. Med. 178 (1993) 1097-1102
26. Ochs H.D., Hollenbaugh D., and Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin. Immunol. 6 (1994) 337-341
27. Offit K., Lo Coco F., Louie D.C., Parsa N.Z., Leung D., Portlock C., Ye B.H., Lista F., Filippa D.A., Rosenbaum A., et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N. Engl. J. Med. 331 (1994) 74-80
28. Oster B., Bundgaard B., Hupp T.R., and Hollsberg P. Human herpesvirus 6B induces phosphorylation of p53 in its regulatory domain by a CK2- and p38-independent pathway. J. Gen. Virol. 89 (2008) 87-96
29. Pasqualucci L., Migliazza A., Basso K., Houldsworth J., Chaganti R., and Dalla-Favera R. Mutations of the BCL-6 proto-oncogene disrupt its negative autoregulation in diffuse large cell lymphoma. Blood 101 (2003) 2914-2923
30. Polo J.M., Dell'Oso T., Ranuncolo S.M., Cerchietti L., Beck D., Da Silva G.F., Prive G.G., Licht J.D., and Melnick A. Specific peptide interference reveals Bcl-6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 10 (2004) 1329-1335
31. Raman M., Chen W., and Cobb M.H. Differential regulation and properties of MAPKs. Oncogene 26 (2007) 3100-3112
32. Reljic R., Wagner S.D., Peakman L.J., and Fearon D.T. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J. Exp. Med. 192 (2000) 1841-1848
33. Revy P., Muto T., Levy Y., Geissmann F., Plebani A., Sanal O., Catalan N., Forveille M., Dufourcq-Labelouse R., Gennery A., Tezcan I., Ersoy F., Kayserili H., Ugazio A.G., Brousse N., Muramatsu M., Notarangelo L.D., Kinoshita K., Honjo T., Fischer A., and Durandy A. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102 (2000) 565-575
34. Saito M., Gao J., Basso K., Kitagawa Y., Smith P.M., Bhagat G., Pernis A., Pasqualucci L., and Dalla-Favera R. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12 (2007) 280-292
35. Sale J.E., and Neuberger M.S. TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Immunity 9 (1998) 859-869
36. Scheeren F.A., Naspetti M., Diehl S., Schotte R., Nagasawa M., Wijnands E., Gimeno R., Vyth-Dreese F.A., Blom B., and Spits H. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat. Immunol. 6 (2005) 303-313
37. Schreiber E., Matthias P., Müller M., and Schaffner W. Rapid detection of octamer binding protein with "mini-extracts" prepared from a small number of cells. Nucl. Acids Res. 17 (1989) 6419
38. Shvarts A., Brummelkamp T.R., Scheeren F., Koh E., Daley G.Q., Spits H., and Bernards R. A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev. 16 (2002) 681-686
39. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., and McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18 (2004) 189-218
40. Sutherland C.L., Heath A.W., Pelech S.L., Young P.R., and Gold M.R. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J. Immunol. 157 (1996) 3381-3390
41. Tunyaplin C., Shaffer A.L., Angelin-Duclos C.D., Yu X., Staudt L.M., and Calame K.L. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J. Immunol. 173 (2004) 1158-1165
42. Vyas P., Vickers M.A., Simmons D.L., Ayyub H., Craddock C.F., and Higgs D.R. Cis-acting sequences regulating expression of the human alpha-globin cluster lie within constitutively open chromatin. Cell 69 (1992) 781-793
43. Walker S.R., Nelson E.A., and Frank D.A. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 26 (2007) 224-233
44. Wang X., Li Z., Naganuma A., and Ye B.H. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15018-15023
45. Wang X., Rao J., and Studzinski G.P. Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells. Exp. Cell Res. 258 (2000) 425-437
46. Wykes M., Poudrier J., Lindstedt R., and Gray D. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur. J. Immunol. 28 (1998) 548-559
47. Ye B.H., Cattoretti G., Shen Q., Zhang J., Hawe N., de Waard R., Leung C., Nouri-Shirazi M., Orazi A., Chaganti R.S., Rothman P., Stall A.M., Pandolfi P.P., and Dalla-Favera R. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 16 (1997) 161-170
48. Ye B.H., Lo Coco F., Chang C.C., Zhang J., Migliazza A., Cechova K., Knowles D.M., Offit K., Chaganti R.S., and Dalla-Favera R. Alterations of the BCL-6 gene in diffuse large-cell lymphoma. Curr. Top. Microbiol. Immunol. 194 (1995) 101-108
49. Ye B.H., Rao P.H., Chaganti R.S., and Dalla-Favera R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res. 53 (1993) 2732-2735